21-gene recurrence score may underestimate benefit of chemotherapy for young non-Hispanic Black women with ER-positive, axillary node-negative breast cancer.

Adding palbociclib to letrozole did not improve OS in postmenopausal patients with ER+, HER2- advanced breast cancer in the PALOMA-2 trial.

Fulvestrant alone or in combination with anastrozole did not provide a benefit over anastrozole alone as neoadjuvant therapy for postmenopausal, ER-rich, HER2-negative, stage II-III breast cancer.

Highest cumulative risks for invasive breast cancer and breast cancer death seen for women aged younger than 45 years at diagnosis.

Molecular subtype-based treatment can improve outcomes in patients with recurrent or metastatic triple-negative breast cancer, a phase 2 trial suggests.

A review of common therapies for advanced breast cancer and the common adverse effects patients may experience.

Second breast cancers were most often imaging-detected or patient-detected, with only 2.2 percent detected by physician.

Women undergoing breast-conserving surgery or mastectomy more likely to be treated at specialist breast reconstruction centers.

Bevacizumab, etoposide, and cisplatin given before whole-brain radiotherapy may help control brain metastases in patients with breast cancer.

An interview study sought to understand older female patients’ perspectives on mammography screening, particularly among women older than 75.